GoalVest Advisory LLC Cuts Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

GoalVest Advisory LLC lessened its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 23.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 645 shares of the medical research company’s stock after selling 201 shares during the quarter. GoalVest Advisory LLC’s holdings in Edwards Lifesciences were worth $48,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EW. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the third quarter valued at $32,000. Avior Wealth Management LLC grew its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $40,000. Finally, JFS Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock valued at $2,195,180 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.4 %

Edwards Lifesciences stock opened at $68.99 on Thursday. The company has a market capitalization of $40.69 billion, a P/E ratio of 9.96, a PEG ratio of 3.59 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a 50-day simple moving average of $72.20 and a 200-day simple moving average of $70.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm earned $0.59 EPS. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on EW. JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Citigroup boosted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Piper Sandler cut their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, The Goldman Sachs Group boosted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.